Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets several pathways relevant for AD but distinct from current treatments ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, ...

Inflammation and mitochondrial function as mechanisms in accelerated aging (AA) across substance use disorders (SUDs). This ...

Scientists have uncovered a surprising trick used by the herpes simplex virus to wake up inside the body. Researchers at the ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

A study published in the Journal of Cosmetic Dermatology explores the potential of Djon Djon, a unique mushroom fermented by ...

Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

enabling the initiation of a Phase 1 trial, which is anticipated to begin in Q2 2025. “GS-6791/NX-0479 is a highly optimized, selective, oral degrader of IRAK4, a master regulator of IL-1R/TLR ...

Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration, FDA, has cleared the IND for the IRAK4 degrader ...